嘉应制药
(002198)
| 流通市值：30.91亿 | | | 总市值：30.91亿 |
| 流通股本：5.08亿 | | | 总股本：5.08亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 121,632,944.06 | 376,167,156.57 | 259,604,624.04 | 180,201,567.26 |
| 营业收入 | 121,632,944.06 | 376,167,156.57 | 259,604,624.04 | 180,201,567.26 |
| 二、营业总成本 | 101,544,275.2 | 349,185,997.89 | 256,532,928.46 | 175,374,905.21 |
| 营业成本 | 40,369,560.36 | 150,722,980.96 | 110,541,535.59 | 78,865,625.27 |
| 税金及附加 | 1,962,224.32 | 7,188,491.9 | 4,793,445.6 | 3,259,586.97 |
| 销售费用 | 44,206,430.98 | 137,401,217.09 | 103,992,488.16 | 70,416,333.35 |
| 管理费用 | 13,474,828.62 | 48,485,607.56 | 32,779,996.48 | 19,523,355.14 |
| 研发费用 | 1,699,113.63 | 6,757,234.58 | 5,583,739.76 | 4,151,551.22 |
| 财务费用 | -167,882.71 | -1,369,534.2 | -1,158,277.13 | -841,546.74 |
| 其中:利息费用 | - | 3,955.04 | - | 212.54 |
| 其中:利息收入 | 182,881.75 | 1,408,500.11 | 1,182,665.06 | 861,844.43 |
| 加:公允价值变动收益 | -499,543 | - | 127,440.66 | 162,947.51 |
| 加:投资收益 | -352,280 | 675,010.43 | 590,765.52 | 988,875.28 |
| 资产处置收益 | 120.92 | 1,606,951.4 | 1,606,951.4 | 1,602,244.41 |
| 资产减值损失(新) | - | -1,190,339.63 | -854,420.55 | -1,227,007.76 |
| 信用减值损失(新) | - | -4,030,242.59 | -353,872.07 | -301,414.86 |
| 其他收益 | 90,263.76 | 1,215,061.69 | 525,226.87 | 376,527.84 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 19,327,230.54 | 25,257,599.98 | 4,713,787.41 | 6,428,834.47 |
| 加:营业外收入 | 99,002.13 | 291,258.51 | 271,919.19 | 271,920.76 |
| 减:营业外支出 | 86,919.96 | 453,781.12 | 178,372.42 | 107,650 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 19,339,312.71 | 25,095,077.37 | 4,807,334.18 | 6,593,105.23 |
| 减:所得税费用 | 3,936,055.53 | 4,483,477.82 | 1,933,988.23 | 925,365.31 |
| 六、净利润 | 15,403,257.18 | 20,611,599.55 | 2,873,345.95 | 5,667,739.92 |
| 持续经营净利润 | 15,403,257.18 | 20,611,599.55 | 2,873,345.95 | 5,667,739.92 |
| 归属于母公司股东的净利润 | 15,403,257.18 | 20,611,599.55 | 2,873,345.95 | 5,667,739.92 |
| (一)基本每股收益 | 0.03 | 0.04 | 0.01 | 0.01 |
| (二)稀释每股收益 | 0.03 | 0.04 | 0.01 | 0.01 |
| 九、综合收益总额 | 15,403,257.18 | 20,611,599.55 | 2,873,345.95 | 5,667,739.92 |
| 归属于母公司股东的综合收益总额 | 15,403,257.18 | 20,611,599.55 | 2,873,345.95 | 5,667,739.92 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-31 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |